Kristen Ambrose - Feb 24, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
SVP & Chief Accounting Officer
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 24, 2023
Transactions value $
-$492,211
Form type
4
Date filed
2/28/2023, 03:44 PM
Previous filing
Feb 3, 2023
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$145K -502 -5.57% $289.12 8.51K Feb 24, 2023 Direct
transaction VRTX Common Stock Sale -$282K -982 -11.54% $287.25 7.53K Feb 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$52.8K -183 -2.43% $288.68 7.35K Feb 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$12.2K -42 -0.57% $289.63 7.3K Feb 27, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1.
F2 Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71).
F4 Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17).